ALSO NOTED: Pharmaxis drug gains fast track status; EC approves UCB/Schwarz acquisition; and much more...

> Belgium-based UCB has been granted permission by the European Commission to complete it's planned acquisition of Germany's Schwarz Pharma for about $5.6. Report

> Shares of Australia-based Pharmaxis surged on news that the company's cystic fibrosis drug Bronchitol has received fast track status from the FDA. Report

> A new report finds that the pharmaceutical market in India is set to grow by 10 percent by the year 2010. Release

> The National Human Genome Research Institute has granted tens of millions of dollars to three major sequencing centers. Report

> Two researchers at University College London have used printing technology to weave polymer nanofibers together in a way that may eventually allow them to develop living tissue that can be used to repair the body. Report  

> Researchers at the Salk Institute for Biological Studies have published the results of a study in which they activated the Wnt signaling system in the embryo of a chicken, which allowed it to grow back a wing that had been removed. Report

And Finally… The FDA is already receiving criticism for allowing silicone implants back on the market. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.